{"url_path":"/sec/gtbp/8-k/2026-06-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-028457-index.html","accession_number":"0001493152-26-028457","cik":"0000109657","ticker":"GTBP","issuer_name":"GT Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-028457-index.html","primary_entity_key":"0000109657","primary_entity_name":"GT Biopharma, Inc."},"word_count":82,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n \n \n \n\n3.1\n \n[Amendment No. 1 to the Amended and Restated Bylaws of GT Biopharma, Inc.](ex3-1.htm)\n\n104\n \nCover\nPage Interactive Data File, formatted in Inline XBRL\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**GT\nBIOPHARMA, INC.**\n\n \n \n\nDate:\nJune 12, 2026\nBy:\n*/s/\nAlan Urban*\n\n \n \nAlan\nUrban\n\n \n \nChief\nFinancial Officer"}